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The fragile X mental retardation protein (FMRP) is an RNA-binding protein that regulates
mRNA metabolism. FMRP has been largely studied in the brain, where the absence of
this protein leads to fragile X syndrome, the most frequent form of inherited intellectual
disability. Since the identification of the FMRP gene in 1991, many studies have primarily
focused on understanding the function/s of this protein. Hundreds of potential FMRP
mRNA targets and several interacting proteins have been identified. Here, we report
the identification of FMRP mRNA targets in the mammalian brain that support the key
role of this protein during brain development and in regulating synaptic plasticity. We
compared the genes from databases and genome-wide association studies with the brain
FMRP transcriptome, and identified several FMRP mRNA targets associated with autism
spectrum disorders, mood disorders and schizophrenia, showing a potential common
pathway/s for these apparently different disorders.
Keywords: fragile X syndrome, autism, schizophrenia, major depressive disorders, FMRP, RNA-binding proteins,
synaptic plasticity, local protein synthesis
INTRODUCTION
Protein synthesis at subcellular sites is a well-conserved mech-
anism that allows the rapid expression of specific genes in
response to localized cues (Xing and Bassell, 2013). During
transport, mRNAs are stabilized via association with multiple
and different trans-acting factors, such as RNA-binding pro-
teins (RBPs) and non-coding RNAs, forming ribonucleoparticles
(RNPs) that vary in size and composition during cell cycle and
development.
In highly polarized cells, such as neurons, mRNAs are trans-
ported from the nucleus to dendrites and axons where these
molecules undergo local translation and degradation (Steward
and Schuman, 2003; Bramham, 2008; Cajigas et al., 2010; Doyle
and Kiebler, 2012; Hornberg and Holt, 2013) according to their
subcellular localization and cellular inputs (Bramham, 2008).
RNA-binding proteins recognize and bind mRNA targets
through regulatory elements in the 5′ and 3′ untranslated regions
(UTRs) (Pichon et al., 2012), and in some cases the coding regions
are also involved in these interactions (Anko and Neugebauer,
2012). Binding to mRNAs is mediated through well-known RNA-
binding motifs, which are often present in multiple copies (Clery
et al., 2008) and typically bind short RNA sequences (Anko
and Neugebauer, 2012). Several RBPs cooperate for the binding
of mRNA, thereby increasing the specificity of this interaction
(Matlin et al., 2005; Ule and Darnell, 2006). The actin cytoskele-
ton might well facilitate RNA recognition, as this structure asso-
ciates with RBPs and coordinates the binding of these proteins to
mRNA (Percipalle, 2009). However, individual RBPs bind to sev-
eral mRNAs. Themulti-targeted binding property of RBPs has led
to a model of regulated gene expression in eukaryotes termed “the
post-transcriptional operon” (Keene, 2007).
The fragile X mental retardation protein (FMRP) is a widely
studied RBP in the brain. Silencing of the FMR1 gene encoding
FMRP leads to fragile X mental retardation syndrome (FXS), the
most common cause of inherited intellectual disability (Bagni
et al., 2012). A majority of the clinical cases of FXS reflect a lack
of FMRP due to a large trinucleotide CGG-repeat expansion in
the 5′ UTR of the gene, resulting in FMR1 gene silencing. Rare
cases have been reported to carry partially deleted or mutated
FMRP (De Boulle et al., 1993; Mila et al., 2000; Coffee et al.,
2008; Collins et al., 2010). The FMR1 gene and FMRP have also
been associated with the pathogenesis of other disorders, such as
fragile X-associated tremor ataxia syndrome (FXTAS), premature
ovarian failure (POF), and autism spectrum disorder (ASD)
(Bagni et al., 2012).
Here, we briefly reviewed the structure and function of FMRP,
a multifunctional RBP that regulates the transport, stability and
local protein synthesis of hundreds of RNAs in the brain. We fur-
ther discuss how anomalies in the expression of FMRP alter the
condition of its targets and ultimately, highlight a subset of FMRP
target mRNAs dysregulated in autism spectrum disorders (ASDs),
mood disorders (MDs) including bipolar disorder (BD), major
depressive disorder (MDD), attention deficit hyperactive disorder
(ADHD), and schizophrenia (SCZ).
FMRP STRUCTURE, RNA TARGETS AND PROTEIN PARTNERS
The human FMR1 gene is ubiquitously expressed (https://www.
genevestigator.com/gv/), with higher abundance in some tissues
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(Kaufmann et al., 2002; Xie et al., 2009). The gene comprises 17
exons spanning 38 kb of Xq27.3 (Eichler et al., 1993). Alternative
splicing of the gene results in the generation of 12 protein iso-
forms (De Boulle et al., 1993; Brackett et al., 2013).
In the mammalian brain, FMRP targets hundreds of mRNAs
(Miyashiro et al., 2003; Darnell et al., 2011; Bagni et al., 2012;
Gross et al., 2012; Wang et al., 2012) and non-coding RNAs, such
as the brain cytoplasmic RNA BC1/BC200 in vitro and in vivo
(Zalfa et al., 2003, 2005; Gabus et al., 2004; Johnson et al., 2006;
Lacoux et al., 2012) and a few microRNAs (Jin et al., 2004;
Edbauer et al., 2010; Gessert et al., 2010; Muddashetty et al., 2011;
Tian et al., 2013).
Structural studies of the FMRP domain have contributed to
the understanding of the molecular function/s of this protein.
The N-terminal region, characterized by the presence of two
Tudor domains (TD)(Ramos et al., 2006), binds in vitro RNA
homopolymers and the small non-coding BC1 RNA (Gabus et al.,
2004; Zalfa et al., 2005; Lacoux et al., 2012) (Figure 1). The
central region contains two K homology domains (KH) and a
nuclear export signal (NES) (Valverde et al., 2008). The most
severe single point mutation identified in a patient with FXS is
an lle367Asn, located on helix α2 of the KH2 domain (De Boulle
et al., 1993). The murine FMRP, carrying the corresponding
mutation (Ile304Asn), loses the ability to bind RNA (Zang et al.,
2009), likely reflecting the destabilization of the hydrophobic
core, which partially unfolds the domain (Di Marino et al., 2013).
A recent study in non-neuronal cells has shown that the FMRP
Ile304Asn mutation reduces the binding affinity of a subset of
mRNAs, such as neurofibromatosis type 1 (NF1), FMR1, bifunc-
tional glutamate/proline-tRNA ligase (EPRS), serine/threonine-
protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA),
ubiquitin-protein ligase E3A (UBE3A), structural maintenance
of chromosomes protein 1A (SMC1A) and cohesin subunit SA-2
(STAG2) (Ascano et al., 2012).
The C-terminal region, containing an RGG box, is involved
in the interaction of well-characterized FMRP mRNA targets
(Darnell et al., 2001; Menon and Mihailescu, 2007; Westermark
and Malter, 2007; Zalfa et al., 2007; Menon et al., 2008; Blackwell
et al., 2010). The C-terminal region of FMRP binds post synap-
tic protein-95 (PSD-95) mRNA (Zalfa et al., 2007), microtubule
associated protein 1B (MAP1B) (Darnell et al., 2001; Zalfa et al.,
2003), semaphorin 3F (SEMA3F) (Menon and Mihailescu, 2007),
extracellular matrix protein 2 (SC1), brain acid soluble protein 1
(NAP22) (Darnell et al., 2001) and serine/threonine-protein kinase
LMTK1 (AATYK) (Blackwell et al., 2010) mRNAs, a few of which
are depicted in Figure 1.
FMRP homodimerises and interacts with several cytoplas-
mic and nuclear proteins involved in mRNA metabolism and
cytoskeleton-remodeling proteins (Bagni and Klann, 2012).
Among the best characterized FMRP-interacting proteins are
FIGURE 1 | FMRP exon structure comprising its functional domains.
Upper frame: The red box at the N-terminus of exon 1 indicates the location
of the CGG triplet repeat within the 5′ UTR of the mRNA. The four RNA
binding domains are: the N-terminus, the two K homology domains (KH1 and
KH2) and the RGG box. Middle frame: FMRP domains interacting with
NUFIP1, CYFIP1, CYFIP2, FXR1P, FXR2P, TDRD3, and SMN proteins. The
FMRP amino acid sequence involved in these interactions is shown between
the brackets. The nuclear localization signal (NLS) and the nuclear export
signal (NES) are also indicated. Lower frame: The FMRP RNA binding
domains and the RNA/mRNA targets directly bound are indicated.
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protein argonaute-2 (Ago2) (Muddashetty et al., 2011), 58 kDa
microspherule protein (MSP58) (Davidovic et al., 2006), nuclear
fragile X mental retardation-interacting proteins 1 and 2
(NUFIP1 and 2) (Bardoni et al., 2003), the survival of motor neu-
ron (SMN) (Piazzon et al., 2008), the Tudor domain-containing
protein 3 (Linder et al., 2008), nuclear export factor 2 (NXF2)
(Zhang et al., 2007), dicer (Cheever and Ceman, 2009), cyto-
plasmic interacting protein CYFIP1 (Schenck et al., 2001, 2003;
Napoli et al., 2008; De Rubeis et al., 2013) and the two paralogs,
fragile X-related proteins 1 and 2 (FXRP1 and FXRP2) (Tamanini
et al., 1999) (Figure 1).
CELLULAR AND MOLECULAR FUNCTIONS OF FMRP
Although in neurons, FMRP has been localized in the nucleus,
cell body and dendrites (Willemsen et al., 1996), the cytoplas-
mic function of FMRP has been the most studied. FMRP forms
large cytoplasmic RNPs containing several proteins and RNAs,
and this protein is involved in the transport, stability and transla-
tion of several mRNAs (Bagni et al., 2012). One report suggested
FMRP might also function as splicing enhancer (Didiot et al.,
2008). Additionally, Drosophila FMRP has been related to the
RNA-editing pathway (Bhogal et al., 2011).
REGULATION OF mRNA TRANSPORT
FMRP transports RNA/mRNAs from the cell body to synapses in
an activity-dependentmanner and through a dynamic association
with microtubule motors (Kanai et al., 2004; Antar et al., 2005;
Ferrari et al., 2007; Dictenberg et al., 2008; Charalambous et al.,
2013). FMRP granules transport mRNA including its own (Antar
et al., 2004; Ferrari et al., 2007; Kao et al., 2010), and the absence
of FMRP impairs the localization of Map1b and SAP90/PSD-95-
associated protein 4 (Sapap4) mRNAs, thus altering the proper
synthesis of these proteins at synapses (Dictenberg et al., 2008;
Kao et al., 2010).
REGULATION OF mRNA STABILITY
Initial studies performed in Fmr1 KO mice have revealed that the
absence of FMRP alters the abundance of hundreds of mRNAs
in the brain (Brown et al., 2001; Miyashiro et al., 2003; Gantois
et al., 2006); a few mRNAs were found to be down regulated
in all three studies. Further analyses on specific mRNAs showed
that dysregulation occurred in specific brain areas and/or sub-
cellular compartments, suggesting that FMRP might regulate the
same mRNA in multiple ways (Miyashiro et al., 2003). FMRP
modulates the stability of certain mRNAs by preventing or sus-
taining mRNA decay (De Rubeis and Bagni, 2010). As an example
of the two opposite activities on different mRNAs, it has been
shown that hippocampal FMRP protects PSD-95 mRNA from
decay (Zalfa et al., 2007) in an activity-dependent manner; how-
ever, FMRP protein also facilitates the decay of nuclear RNA
export factor 1 (NXF1) mRNA in mouse neuroblastoma (N2a)
cells (Zhang et al., 2007). Furthermore, FMRP regulates PSD-95
mRNA stability in the hippocampus (Zalfa et al., 2007) and reg-
ulates translation at cortical synapses (Muddashetty et al., 2007).
PSD-95mRNA is an important player in synaptic plasticity and is
affected in ASD (Feyder et al., 2010) and SCZ (Toro and Deakin,
2005).
The cortical region of the Fmr1 KO mouse brain shows
the reduced expression of different GABAA receptor subunits
(El Idrissi et al., 2005; Gantois et al., 2006), consistent with
evidence of imbalanced GABAergic signaling in FXS patients.
Taken together, FMRP-RNPs might play different roles in several
brain regions and regulate mRNAs through different mechanisms
according to the developmental stage and subcellular localization.
REGULATION OF mRNA TRANSLATION
The translational dysregulation of FMRP mRNA targets
significantly contributes to the FXS phenotype (Bagni et al.,
2012; Darnell and Klann, 2013). Initial studies performed in
lymphoblastoid cells derived from FXS individuals showed an
increased translation rate in several FMRP targets (Brown et al.,
2001). The increased translation of FMRPmRNA targets was also
observed in Fmr1 KO mice specifically at synapses, consistent
with the idea that FMRP functions as a repressor of translation
(Muddashetty et al., 2007; Narayanan et al., 2007; Napoli et al.,
2008; De Rubeis et al., 2013).
FMRP activity is regulated in response to different recep-
tor signaling cascades, i.e., type I metabotropic glutamate
receptors (mGluRs) (Huber et al., 2002), the 2-amino-3-(5-
methyl-3-oxo-1,2-ox-azol-4-yl) propanoic acid (AMPA) recep-
tors (Nakamoto et al., 2007), the γ-aminobutyric acid (GABA)
receptors (Centonze et al., 2008; Curia et al., 2009; Shang et al.,
2009), the N-methyl-D-aspartate (NMDA) receptors (Suvrathan
et al., 2010; Yun and Trommer, 2011; Eadie et al., 2012), the
tyrosine kinase or BDNF/NT-3 growth factor (TrkB) receptors
(Napoli et al., 2008; Louhivuori et al., 2011; De Rubeis et al.,
2013), the dopamine (DA) receptors (Wang et al., 2008) and
recently the cannabinoid receptors (Maccarrone et al., 2010;
Busquets-Garcia et al., 2013).
One of the most affected and best characterized signaling
cascades in fragile X is the mGluR (Bear et al., 2004). Upon
mGluR receptor activation, FMRP-mediated translational block
is released and protein synthesis can ensue. In the absence of
FMRP, the increase in protein synthesis results in a receptor
imbalance; an increase in the mGluR1 and mGluR5 activity and
the reduced insertion of AMPA receptors at the surface that leads
to enhanced mGluR long-term depression (mGluR-LTD) (Bear
et al., 2004).
mGluR-LTD is a form of synaptic plasticity that involves
mRNA targeting and local protein synthesis and degradation
(Bear and Malenka, 1994), and this condition can be induced
through the application of (S)-3,5-dihydroxyphenylglycine
(DHPG) (Wisniewski and Car, 2002) in a protein synthesis-
independent manner (Huber et al., 2002). In Fmr1 KO mice,
DHPG-induced LTD is strongly increased and these electrophys-
iological phenotypes established the “mGluR theory” in FXS
(Bear et al., 2004).
FMRP activity is regulated through posttranslational mod-
ifications. DHPG-induced LTD also activates FMRP synthesis
at synapses (Antar et al., 2004; Ferrari et al., 2007; Kao et al.,
2010), which in turn is quickly degraded through the ubiquitin-
proteasome system (Hou et al., 2006). The effect of FMRP on
protein synthesis is influenced by the phosphorylation status of
FMRP (Ceman et al., 2003), via the mTOR pathway (Narayanan
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et al., 2007): phosphorylated FMRP represses translation, while
dephosphorylated FMRP releases the inhibition, allowing protein
synthesis to ensue, a mechanism similarly shown for previously
characterized eukaryotic initiation factor 4E binding proteins
(eIF4E-BPs) in non-neuronal cells (Richter and Klann, 2009).
FMRP has also been detected in P bodies (PB), stress granules
(SG) (Kedersha et al., 2005), and cytoplasmic structures, contain-
ing translationally silent pre-initiation complexes. FMRP is part
of mRNPs (Siomi et al., 1996; Laggerbauer et al., 2001; Ishizuka
et al., 2002; Zalfa et al., 2003; Anderson and Kedersha, 2006;
Monzo et al., 2006; Papoulas et al., 2010; Charalambous et al.,
2013), supporting the function of FMRP as a translational repres-
sor at the initiation level, as observed at synapses both in vitro
(Laggerbauer et al., 2001) and in vivo (Napoli et al., 2008; De
Rubeis et al., 2013).
We have shown that FMRP represses translation through its
binding to CYFIP1, a neuronal eIF4E-BP (Napoli et al., 2008).
CYFIP1 binds to eIF4E, blocking the initiation of translation.
Subsequently, the synaptic stimuli CYFIP1-FMRP complex is
released from eIF4E and translation ensues (Napoli et al., 2008).
Notably, CYFIP1 is also implicated in actin cytoskeleton remodel-
ing (Kobayashi et al., 1998; Eden et al., 2002; Schenck et al., 2003;
Stradal et al., 2004; Chen et al., 2010). We have recently shown
that CYFIP1 links local protein synthesis and actin dynamics (De
Rubeis et al., 2013). FMRP has also been proposed to regulate
mRNA elongation (Darnell et al., 2011).
FXS AND COMMONALITIES WITH OTHER DISEASES
FXS is the most common monogenic cause of ASD, and 30%
of patients with FXS present autistic behaviors (Bagni et al.,
2012). Early studies performed on heterozygous females carry-
ing the fragile X mutant gene showed a greater frequency of
psychopathologies associated with schizophrenia spectrum diag-
noses (Reiss et al., 1988). Furthermore, carriers of premutated
FMR1 alleles (reduced FMRP levels) have been associated with a
significant degree of psychiatric disorders (Bourgeois et al., 2009).
Recently, low FMRP levels have been detected in the postmortem
brain from subjects with SCZ, BD and MDD (Fatemi et al., 2010;
Kelemen et al., 2013; Kovacs et al., 2013) and in blood samples
from schizophrenia patients (Kovacs et al., 2013). Some individu-
als that display psychoses also carry FMR1 full and pre-mutations
(Jonsson et al., 1995; Ashworth et al., 1996; Khin et al., 1998).
It is not known whether decreased levels of FMRP are the
cause or the consequence of the development of these disorders.
However, it is tempting to speculate that the loss or reduced func-
tion of FMRP might lead to a dysregulation of particular FMRP
target genes associated with ASD, SCZ, and MD, suggesting the
correlation of certain FXS features with these neuronal disorders.
Because the GABAergic system is dysfunctional in these disorders
(Kelemen et al., 2013) and the lack of FMRP affects the expres-
sion of some GABA receptor subunits (D’Hulst and Kooy, 2007),
it is reasonable to hypothesize that FMRP reductionmight explain
the alterations of proteins associated with the GABAergic system
in these different neurological diseases. Indeed, recent findings
showed that a selective activator of GABAB receptor reversed
some FXS associated pathologies (Henderson et al., 2012).
It cannot be ruled out that certain proteins, which are risk
factors for ASD, SCZ and/or MD, work together with FMRP
and might disrupt the function of this protein in a disease con-
text. Recently, it has been observed that topoisomerase Top3β,
a risk gene for SCZ and ASD (Iossifov et al., 2012; Xu et al.,
2012; Stoll et al., 2013), binds to FMRP and modifies the func-
tion of this protein in vitro, thereby supporting normal neu-
rodevelopment and averting mental disorders (Xu et al., 2013).
In addition, the authors observed that the disruption of either
Top3β or Fmr1 genes in Drosophila led to a dysregulation of
ptk2, which is genetically associated with SCZ (Walsh et al.,
2008). Notably, CYFIP1 has been associated with ASD (Sahoo
et al., 2006) (Doornbos et al., 2009; Van Der Zwaag et al., 2010;
Von Der Lippe et al., 2010; Talebizadeh et al., 2013), SCZ and
epilepsy (Sahoo et al., 2006; Tam et al., 2010; Zhao et al., 2012).
In addition, we have recently shown that the CYFIP1 interac-
tome contains many novel proteins associated with ASD, SCZ,
and MDD, providing new perspectives to define the regula-
tory pathways shared by neurological disabilities characterized
by spine dysmorphogenesis (De Rubeis et al., 2013), a com-
mon feature of several neuropsychiatric disorders (Penzes et al.,
2011).
Over the last 10 years, several hundred putative
FMRP mRNA targets have been identified in the brain
FIGURE 2 | Venn diagram of FMRP mRNA targets associated with
autistic spectrum disorder (ASD), schizophrenia (SCZ) and mood
disorder (MD). FMRP neuronal target genes (1169) were compared with de
novo gene disruptions (nonsense, splice and frameshifts) reported in GWAS
are associated with ASD, as previously described (Iossifov et al., 2012;
Neale et al., 2012; O’roak et al., 2012b; Sanders et al., 2012), the 528 genes
from the SFARI (https://sfari.org/resources/sfari-base) and the 304 genes
from the AutDB databases (http://autism.mindspec.org/autdb/Welcome.do).
Approximately 120 FMRP target genes were associated with ASD
(in black). Among the 120 target genes, included 35 genes were identified
from the GWAS (in red) and 100 genes were identified from the two
databases (in black). Fifteen genes showed overlap between the GWAS,
the SFARI, and AutDB databases (in black/red color). The 1169 FMRP target
genes were compared with the genes associated with SCZ and MD in the
NHGRI GWAS database (http://www.genome.gov/gwastudies/) and 26
common FMRP targets were shown.
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(Brown et al., 2001; Chen et al., 2003; Miyashiro et al., 2003; Zalfa
et al., 2003, 2007; Muddashetty et al., 2007; Darnell et al., 2011),
and more than 6000 targets have been identified in non-neuronal
cells (Ascano et al., 2012). While these analyses have expanded
the number of FMRP targets, further studies are required to elu-
cidate the extent to which each mRNA contributes to the FXS
clinical phenotype/s. There is substantial evidence that individu-
als with intellectual disabilities are prone to psychological profiles
independently of the genetic and/or environmental cause (Turk,
2011).
Based on several large-scale studies, the number of FMRP
neuronal target mRNAs is approximately 1,400 (Brown et al.,
2001; Chen et al., 2003; Miyashiro et al., 2003; Darnell et al.,
2011). We compared 1,169 unique (non-overlapping in the men-
tioned studies) FMRPmRNA targets with de novo ASD associated
genes identified through recent genome-wide association stud-
ies (GWAS)(Iossifov et al., 2012; Neale et al., 2012; O’roak et al.,
2012a,b; Sanders et al., 2012), obtained from the SFARI (http://
gene.sfari.org) and the Autism databases (AutDB (http://www.
mindspec.org/autdb.html).
As represented in Figure 2, according to the GWAS, 35 FMRP
target mRNAs are associated with ASD (in red), while the SFARI
and AutDB databases have revealed that 100 FMRP target mRNAs
are candidate genes for ASD (in black). Fifteen genes overlap
between the results obtained in the GWAS and the SFARI and
AutDB databases (in black/red color). This analysis shows that
approximately 10% of the neuronal FMRP targets identified, in
the above-mentioned studies, overlap with the genes associated
with ASDs (120 out of 1169).
We also compared the 1,169 FMRP target mRNAs with
176 genes associated with BD, attention deficit-hyperactivity
disorder (ADHD), mood disorder (MD), and SCZ (GWAS com-
piled by the National Human Genome Research Institute cat-
alog http://www.genome.gov/). Twenty-six (out of 176) FMRP
target mRNAs were also identified in this cohort (Figure 2,
in gray). Because a few genes in this group (10) were also
detected among the FMRP targets in the ASD group, it is
reasonable to hypothesize that ASD, SCZ, and mood dis-
orders (BD, MDD, ADHD) share certain common signaling
pathways.
FUTURE PERSPECTIVES
Post-transcriptional studies have revealed that the FMRP regulon
controls disease-related proteins that affect both neurodevelop-
ment and adult brain plasticity and homeostasis. The emerging
wave of genetic association studies has revealed a large number
of risk genes for several neurodegenerative diseases and neurode-
velopmental disorders, such as SCZ, ASD, and BD (http://www.
genome.gov/gwastudies).
The risk genes for neurodevelopmental disorders, identi-
fied through GWAS, were compared with the list of the
FMRP targets, and the results suggest that several pathways
are dysregulated in FXS and might account for specific FXS
phenotypes.
As the FMRP acts as a protein synthesis repressor, it is reason-
able to propose that the FXS phenotype might reflect the over-
expression of specific genes. However, FMRP not only regulates
gene expression at the translational level, but it also influences
the stability of several mRNAs. Furthermore, to determine the
functional association of the FMRP regulon with the repertoire
of genes altered in individuals carrying ASD, SCZ, and MD, it is
important to investigate the dosage of these genes in individu-
als with FXS. Moreover, FXS is a neurodevelopmental disorder,
and the absence of FMRP could affect the expression of specific
targets at different developmental stages and in different brain
areas. Further studies on FMRP targets and the FMRP interac-
tome at specific developmental stages would help to determine
the cause of these disorders and develop further strategies to
ameliorate FXS.
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